In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regulus microMarkers

Division of Regulus Therapeutics Inc.
www.regulusrx.com

Latest From Regulus microMarkers

Start-Up Quarterly Statistics, Q3 2014

Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device

Deal Watch: Roche Returns To RNAi With Santaris Buyout, While Biogen Re-Ups With Regulus

Bristol will team with start-up financier Allied Minds to convert academic research into clinical candidates, with the pharma getting a license to acquire any backed entity that reaches preclinical stage. Two European firms, Boehringer Ingelheim and Medivir, partner again roughly a decade after a disappointing tie-up in HIV.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Regulus Therapeutics Inc.
  • Senior Management
  • Kleanthis Xanthopoulos, PhD, Pres. & CEO
  • Contact Info
  • Regulus microMarkers
    Phone: (888) 734-8587
    3545 John Hopkins Ct., Ste. 210
    San Diego, CA 92121-1121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register